Cargando…

Prognostic signatures of sphingolipids: Understanding the immune landscape and predictive role in immunotherapy response and outcomes of hepatocellular carcinoma

BACKGROUND: Hepatocellular carcinoma (HCC) is a complex disease with a poor outlook for patients in advanced stages. Immune cells play an important role in the progression of HCC. The metabolism of sphingolipids functions in both tumor growth and immune infiltration. However, little research has foc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Xin, Zhuge, Jinke, Liu, Jinhui, Xia, Zhijia, Wang, Huixiong, Gao, Qiang, Jiang, Hao, Qu, Yanyu, Fan, Linlin, Ma, Jiali, Tan, Chunhua, Luo, Wei, Luo, Yong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10063861/ https://www.ncbi.nlm.nih.gov/pubmed/37006285 http://dx.doi.org/10.3389/fimmu.2023.1153423

Ejemplares similares

Efferocytosis signatures as prognostic markers for revealing immune landscape and predicting immunotherapy response in hepatocellular carcinoma
por: Xu, Ke, et al.
Publicado: (2023)

The Role of Sphingolipids in Cancer Immunotherapy
por: Giussani, Paola, et al.
Publicado: (2021)

Identification of a Novel Immune Landscape Signature for Predicting Prognosis and Response of Endometrial Carcinoma to Immunotherapy and Chemotherapy
por: Liu, Jinhui, et al.
Publicado: (2021)

Machine learning to construct sphingolipid metabolism genes signature to characterize the immune landscape and prognosis of patients with uveal melanoma
por: Chi, Hao, et al.
Publicado: (2022)

Hepatocellular Carcinoma Immune Landscape and the Potential of Immunotherapies
por: Giraud, Julie, et al.
Publicado: (2021)

Sphingolipid Signature of Human Feto-Placental Vasculature in Preeclampsia
por: Del Gaudio, Ilaria, et al.
Publicado: (2020)

Association of survival and genomic mutation signature with immunotherapy in patients with hepatocellular carcinoma
por: Ou, Qiyun, et al.
Publicado: (2020)

Title: Multi-Omics and Immune Landscape of Proliferative LncRNA Signatures: Implications for Risk Stratification and Immunotherapy in Hepatocellular Carcinoma
por: Liu, Chi, et al.
Publicado: (2022)

Severity of COVID-19 Patients Predicted by Serum Sphingolipids Signature
por: Torretta, Enrica, et al.
Publicado: (2021)

The Equilibria of Sphingolipid-Cholesterol and Sphingolipid–Sphingolipid in Monolayers at the Air–Water Interface
por: Petelska, Aneta Dorota, et al.
Publicado: (2012)

HVPG signature: A prognostic and predictive tool in hepatocellular carcinoma
por: Qi, Xiaolong, et al.
Publicado: (2016)

Understanding the immune response and the current landscape of immunotherapy in pancreatic cancer
por: Ostios-Garcia, Lorena, et al.
Publicado: (2021)

The Landscape of Using Glycosyltransferase Gene Signatures for Overall Survival Prediction in Hepatocellular Carcinoma
por: Cai, Qiang, et al.
Publicado: (2022)

Current Landscape and Future Directions of Biomarkers for Immunotherapy in Hepatocellular Carcinoma
por: Gok Yavuz, Betul, et al.
Publicado: (2021)

Identification of immune landscape signatures associated with clinical and prognostic features of hepatocellular carcinoma
por: Yan, Hongmei, et al.
Publicado: (2020)

Research landscape and trends of melanoma immunotherapy: A bibliometric analysis
por: Liu, Yanhao, et al.
Publicado: (2023)

Dissecting the effect of sphingolipid metabolism gene in progression and microenvironment of osteosarcoma to develop a prognostic signature
por: Zhong, Yujian, et al.
Publicado: (2022)

Friend or Foe? Locoregional Therapies and Immunotherapies in the Current Hepatocellular Treatment Landscape
por: Young, Shamar, et al.
Publicado: (2023)

Identification of a prognostic gene signature based on an immunogenomic landscape analysis of bladder cancer
por: Luo, Yongwen, et al.
Publicado: (2020)

Landscape of Prognostic m6A RNA Methylation Regulators in Hepatocellular Carcinoma to Aid Immunotherapy
por: Xu, Qianhui, et al.
Publicado: (2021)

Immunotherapy for advanced or recurrent hepatocellular carcinoma
por: Luo, Ying-Zhe, et al.
Publicado: (2023)

Prognostic pyroptosis-related lncRNA signature predicts the efficacy of immunotherapy in hepatocellular carcinoma
por: Cheng, Zina, et al.
Publicado: (2022)

Identification of PANoptosis-Based Prognostic Signature for Predicting Efficacy of Immunotherapy and Chemotherapy in Hepatocellular Carcinoma
por: Xiong, Xiaofeng, et al.
Publicado: (2023)

A novel hepatocellular carcinoma-specific mTORC1-related signature for anticipating prognosis and immunotherapy
por: Chen, Erbao, et al.
Publicado: (2023)

Global research landscape and trends of lung cancer immunotherapy: A bibliometric analysis
por: Liu, Yanhao, et al.
Publicado: (2022)

Co-expression prognostic-related genes signature base on propofol and sevoflurane anesthesia predict prognosis and immunotherapy response in glioblastoma
por: Hou, Zhiqi, et al.
Publicado: (2023)

Identification of a Signature for Predicting Prognosis and Immunotherapy Response in Patients with Glioma
por: Zong, Wei-Feng, et al.
Publicado: (2022)

Sphingolipids in Inflammation
por: Albi, Elisabetta, et al.
Publicado: (2018)

Sphingolipids in COPD
por: Chakinala, Raja Chandra, et al.
Publicado: (2019)

Development of a Costimulatory Molecule Signature to Predict Prognosis, Immune Landscape, and Response to Immune Therapy for Hepatocellular Carcinoma
por: Zhou, Yongjie, et al.
Publicado: (2022)

Pyroptosis-Related Risk Signature Exhibits Distinct Prognostic, Immune, and Therapeutic Landscapes in Hepatocellular Carcinoma
por: Zhao, Yidi, et al.
Publicado: (2022)

Development and validation of an ECM-related prognostic signature to predict the immune landscape of human hepatocellular carcinoma
por: Wu, Guozhi, et al.
Publicado: (2022)

Immune landscape and immunotherapy of hepatocellular carcinoma: focus on innate and adaptive immune cells
por: Gao, Xiaoqiang, et al.
Publicado: (2023)

Identification of a Five Immune Term Signature for Prognosis and Therapy Options (Immunotherapy versus Targeted Therapy) for Patients with Hepatocellular Carcinoma
por: Bin, Xiaoyun, et al.
Publicado: (2023)

Engineering Prodrug Nanomedicine for Cancer Immunotherapy
por: Yang, Bin, et al.
Publicado: (2020)

Dissecting the immune cell landscape in hepatocellular carcinoma—are we understanding complexity?
por: Ocker, Matthias
Publicado: (2020)

Immune Cytolytic Activity for Comprehensive Understanding of Immune Landscape in Hepatocellular Carcinoma
por: Takahashi, Hideo, et al.
Publicado: (2020)

A necroptosis -related signature for predicting prognosis and immunotherapy in hepatocellular carcinoma
por: Fu, Xing, et al.
Publicado: (2022)

Sphingolipids in Non-Alcoholic Fatty Liver Disease and Hepatocellular Carcinoma: Ceramide Turnover
por: Simon, Jorge, et al.
Publicado: (2019)

Characterization of stem cell landscape and identification of stemness-relevant prognostic gene signature to aid immunotherapy in colorectal cancer
por: Zheng, Hang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0ojh3sbkdvib7v8aile48b2mla